MedTrace Logo

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-01-12

Study results available
· View outcomes & findings →

Summary

Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.

Conditions

  • Spinocerebellar Ataxias Type 1
  • Spinocerebellar Ataxias Type 2
  • Spinocerebellar Ataxias Type 3
  • Spinocerebellar Ataxias Type 6

Interventions

DRUG

Dalfampridine

Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period

DRUG

Placebo

Placebo will be administered orally every 12 hours, for a 4 week period.

Sponsors & Collaborators

  • Acorda Therapeutics

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Guangbin Xia, MD, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811706 on ClinicalTrials.gov